Shi Luwen

Shi Luwen

  

    Peking University Professor

  Research Areas

  Pharmaceutical Administration

  Clinical Pharmacy

 

  Education & Positions

  Peking University Health Science Center, B.S., 1993

  University of Illinois at Chicago, M.S., 1999

  Vice Dean in School of Pharmaceutical Sciences, Beijing Medical University, 1992-1997

  Chief in Logistics and Infrastructure Department, Peking University Health Science Center, 1997-2000

  Vice Dean, Peking University Health Science Centre, 2000-2005

  Director, Department of Pharmacy Administration and Clinical Pharmacy, School of

  Pharmaceutics Science, Peking University Health Science Center, 2000-

  International Research Centre of Medicinal Administration (IRCMA), Peking University, 2002-

  Assistant Chief, Beijing Municipal Bureau of Health, 2005-2006

 

  Faculty Accolades

  “Scientists in China—People of the Year” 2011

  “Life Mentor” in Peking University Health Science Center 2010

  Xue Muqiao Memorial Award in Price Research 2010

  Outstanding Investigate and Survey Achievement Award of the Price Association of China 2008

  Second Prize on Science and Technology of Beijing 2002

  First Prize of State Education Commission 1995

  Second Prize on Science and Technology Progress of State Administration of Traditional Chinese Medicine 1991

 

  Research Interests

  Our research team spans a broad range of pharmaceutical administration and clinical pharmacy. We study the strategies for the development and reform of medical and health care in China, pharmaceutical policies and laws, strategies for pharmaceutical industry development, pharmacy teaching management and reform, drug utilization and pharmaceutical economics, drug utilization behavior, pharmaceutical care and evaluation system. We also promote the development and teaching system for pharmaceutical administration and clinical pharmacy.

 

  Grants and fundings

  The health and Economic Burden of Bloodstream Infections Caused by Methicillin-resistant Staphylococcus aureus in Chinese Hospitals, 2015 and 2016: A Multicenter Retrospective Cohort Study, funded by China Medical Board.Principal Investigator

  Analysis of Legislation for Protecting Pediatric Drugs, funded by National Health and Family Planning Commission

  Phased Evaluation of Achievements of “Opinions of the State Council on Reforming the Research and Approval System of Medical Devices for Medical Products” ([2015]No.44)

  Pharmacoeconomics Study of Drugs Treating Chronic Kidney Disease

  Principal Investigator

 

  Publications

  Wushouer H, Tian Y, Guan XD, Han S, Shi LW*. Trends and patterns of antibiotic consumption in China's tertiary hospitals: Based on a 5 year surveillance with sales records, 2011-2015. PLoS One. 2017 Dec 27;12(12):e0190314.

  Wushouer H, Zhang ZX, Wang JH, Ji P, Zhu QF, Aishan R, Shi LW*. Trends and relationship between antimicrobial resistance and antibiotic use in Xinjiang Uyghur Autonomous Region, China: Based on a 3 year surveillance data, 2014-2016. J Infect Public Health. 2017 Oct 7. pii: S1876-0341(17)30256-3.

  Guo Z, Guan X, Shi L*. The impacts of implementation of National Essential Medicines Policies on primary healthcare institutions: a cross-sectional study in China[J]. BMC Health Services Research. 2017, 17(1): 723

  Guo N, Iversen T, Lu M, Wang J*, Shi L*. Does the new cooperative medical scheme reduce inequality in catastrophic health expenditure in rural China? BMC Health Serv Res. 2016 Nov 14;16(1):653.

  Xiaoxiong Xin, Xiaodong Guan, Luwen Shi*. Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China. Orphanet Journal of Rare Diseases. 2016,June6; 11:74.